| Gene symbol | USH2A | Synonyms | RP39, US2, USH2, dJ1111A8.1 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1q41 | dbXrefs | |
| Description | usherin | ||||
| GTO ID | GTC0562 |
| Trial ID | NCT05176717 |
| Disease | Retinitis Pigmentosa |
| Altered gene | USH2A |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | QR-421a|ultevursen |
| Phase | Phase2|Phase3 |
| Recruitment status | Terminated |
| Title | A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss |
| Year | 2021 |
| Country | United States|United Kingdom |
| Company sponsor | ProQR Therapeutics |
| Other ID(s) | PQ-421a-004|2021-002728-19 |
| Vector information | |||
|
|||
| Cohort1: dose level 1 | |||||||||||
|
|||||||||||
| Cohort2: dose level 2 | |||||||||||
|
|||||||||||